Zhang Dongrui, Lu Baohua, Liang Bowen, Li Bo, Wang Ziyu, Gu Meng, Jia Wei, Pan Yuanming
Department of Respiratory and Critical Care Medicine, Tianjin Chest Hospital, Tianjin, China.
Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Front Oncol. 2023 May 5;13:1162181. doi: 10.3389/fonc.2023.1162181. eCollection 2023.
Small cell lung cancer (SCLC) is an aggressive and almost universally lethal neoplasm. There is no accurate predictive method for its prognosis. Artificial intelligence deep learning may bring new hope.
By searching the Surveillance, Epidemiology, and End Results database (SEER), 21,093 patients' clinical data were eventually included. Data were then divided into two groups (train dataset/test dataset). The train dataset (diagnosed in 2010-2014, N = 17,296) was utilized to conduct a deep learning survival model, validated by itself and the test dataset (diagnosed in 2015, N = 3,797) in parallel. According to clinical experience, age, sex, tumor site, T, N, M stage (7th American Joint Committee on Cancer TNM stage), tumor size, surgery, chemotherapy, radiotherapy, and history of malignancy were chosen as predictive clinical features. The C-index was the main indicator to evaluate model performance.
The predictive model had a 0.7181 C-index (95% confidence intervals, CIs, 0.7174-0.7187) in the train dataset and a 0.7208 C-index (95% CIs, 0.7202-0.7215) in the test dataset. These indicated that it had a reliable predictive value on OS for SCLC, so it was then packaged as a Windows software which is free for doctors, researchers, and patients to use.
The interpretable deep learning survival predictive tool for small cell lung cancer developed by this study had a reliable predictive value on their overall survival. More biomarkers may help improve the prognostic predictive performance of small cell lung cancer.
小细胞肺癌(SCLC)是一种侵袭性强且几乎普遍致命的肿瘤。目前尚无准确的预后预测方法。人工智能深度学习可能带来新的希望。
通过检索监测、流行病学和最终结果数据库(SEER),最终纳入了21093例患者的临床数据。然后将数据分为两组(训练数据集/测试数据集)。训练数据集(2010 - 2014年诊断,N = 17296)用于构建深度学习生存模型,并同时用其自身和测试数据集(2015年诊断,N = 3797)进行验证。根据临床经验,选择年龄、性别、肿瘤部位、T、N、M分期(美国癌症联合委员会第7版TNM分期)、肿瘤大小、手术、化疗、放疗及恶性肿瘤病史作为预测临床特征。C指数是评估模型性能的主要指标。
预测模型在训练数据集中的C指数为0.7181(95%置信区间,CIs,0.7174 - 0.7187),在测试数据集中的C指数为0.7208(95% CIs,0.7202 - 0.7215)。这些结果表明该模型对SCLC的总生存期具有可靠的预测价值,随后将其打包为Windows软件,供医生、研究人员和患者免费使用。
本研究开发的可解释的小细胞肺癌深度学习生存预测工具对其总生存期具有可靠的预测价值。更多的生物标志物可能有助于提高小细胞肺癌预后预测的性能。